Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$BCRX Q1 '25 Earnings Results & Recap Biocryst Pharmaceuticals (BCRX) exceeded Q1 revenue estimates ($134M vs $127.79M est.) but EPS was flat vs a loss of ($0.08) estimate; full year revenue guidance was raised to $580M-$600M with the company expecting full year profitability, a year ahead of schedule. However, growth may slow in the coming quarters.
3
7

Since Post

Full Details
Top Replies
Iwillbuy
not true the Commercial officer said they expect this paid patient volume to stay relatively stable going forward! What they said the reduction drug act helped with this push for patients to afford costly drugs needed! Don’t mislead people here!
9
doublebtx
So the bearish case is just a bunch of hypothetical worrying and worst case stuff it seems. Management has consistently said they will hit 1B in peak sales for Orladeyo, and they have hit (or exceeded) every financial target thus far. The bearish case is a non factor.
4
Smnorgy1
incorrect bearish info. Listen to the CC.
4

Advertisement|Remove ads.